World Immunization Week

PATH is making lifesaving vaccines more accessible for children around the world.

Donate

Donate

What we do Where we work Who we are Our impact Get involved

What we do

Who we are

Featured

Diversity, equity, and inclusion

Creating a collaborative workplace that challenges the status quo, embraces new ideas, and values different perspectives.

PATH Strategy 2025

The world wasn’t ready for this pandemic, but we can be ready for the next.

Our impact

Featured

UHC by 2030

Universal health coverage (UHC) is for everyone. Realizing the vision of “health for all” will require a historic effort spanning sectors and borders. Everyone has a role to play—we're proud to do our part.

Case studies

Our case studies provide an in-depth examination of the solutions and innovations PATH and partners develop to address the world's most pressing health issues.

Featured

Corporate partners

High-impact corporate partnerships are essential to global health progress. At PATH, we partner with corporations that are innovative, bold, and focused on impact.

Global partners

We are the partner of choice to many of the world's leading governments, multilaterals, and institutional foundations.

Single-Dose HPV Vaccine Evaluation Consortium

Related program: Center for Vaccine Innovation and Access

Since 2018, the Single-Dose HPV Vaccine Evaluation Consortium, coordinated by PATH, has gathered and evaluated data from clinical trials, observational studies, and modeling analyses regarding the value of a single-dose HPV vaccination schedule to protect against cervical cancer.

Results are emerging from several clinical trials evaluating the ability of a single dose of HPV vaccine to elicit a strong immune response against incident and persistent HPV infections, which are the necessary prerequisites to development of cervical lesions and in the longer term, cervical cancer.

The data accumulated to date support the World Health Organization (WHO) endorsement of a single-dose HPV vaccination schedule for substantially reducing the incidence of HPV-attributable cervical precancer and cancer for the primary target of girls aged 9-14 years old and for young women aged 15-20 years old.

Explore and share the evidence using the resources below.

Resources from the Single-Dose HPV Vaccine Evaluation Consortium

Frequently asked questions about single-dose HPV vaccination
This four-page FAQ document provides answers to common questions on current evidence and policy landscape for single-dose HPV vaccination.

Fact sheet: Evidence on single-dose HPV vaccination
This two-page brief provides a snapshot of the evidence supporting WHO’s endorsement of a single-dose HPV vaccination schedule.

Slide deck:
This PowerPoint deck outlines the evidence base in support of a single-dose vaccination schedule. Use the presentation as a guide for meetings with key decision-makers.

External resources

World Health Organization dashboard: National HPV vaccine introduction status

HPV Vaccine Schedule Optimization Guide, October 2023

World Health Organization updated position paper on HPV vaccination schedules, December 2022

WHO Strategic Advisory Group of Experts on Immunization (SAGE) endorsement of a single-dose HPV vaccination schedule, April 2022

Publications on single-dose HPV vaccination

Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results. Nature Medicine. December 2023.

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis. BMC Medicine. August 2023.

Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania. Vaccine. January 2023.

Efficacy of single-dose HPV vaccination among young African women. NEJM Evidence. April 2022

Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. The Lancet Global Health. October 2022.

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial. The Lancet Global Health. March 2022.

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncology. November 2021.

Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine. February 2021.

Evaluation of durability of a single dose of the bivalent HPV vaccine: The CVT trial. Journal of the National Cancer Institute. October 2020.